Article Text

PDF

Minimally invasive direct coronary artery bypass: too young for a trial
  1. MOHAMMAD BASHAR IZZAT,
  2. ANTHONY P C YIM
  1. Division of Cardiothoracic Surgery,
  2. Department of Surgery,
  3. Division of Cardiology,
  4. Department of Medicine,
  5. The Chinese University of Hong Kong,
  6. Hong Kong
  7. email izzat{at}mailserv.CUHK.edu.hk
    1. JOHN E SANDERSON
    1. Division of Cardiothoracic Surgery,
    2. Department of Surgery,
    3. Division of Cardiology,
    4. Department of Medicine,
    5. The Chinese University of Hong Kong,
    6. Hong Kong
    7. email izzat{at}mailserv.CUHK.edu.hk

      Statistics from Altmetric.com

      Recently, a variety of novel approaches and ingenious techniques have been developed in an attempt to make cardiac surgical procedures less invasive.1 Many of these methods remain largely experimental, yet one procedure seems to have been rapidly accepted by cardiac surgeons. In minimally invasive direct coronary artery bypass (MIDCAB) the heart is approached via a right or left anterior mini-thoracotomy through which an internal mammary artery is harvested and anastomosed to the targeted coronary artery under direct vision without the use of cardiopulmonary bypass.2 3 Even though the MIDCAB procedure has been used for complex cases, the most common clinical use of MIDCAB has been for single vessel disease, predominantly involving the left anterior descending coronary artery. Indeed, several recent reports have claimed that the clinical outcome of patients managed with this approach is favourable.2-4

      Not surprisingly, there are calls for randomised controlled trials of MIDCAB against conventional revascularisation or angioplasty in patients with isolated left anterior descending coronary artery disease.5 6 Such trials will certainly be necessary at some stage to establish the role MIDCAB should play in routine practice, nevertheless one must ask the question: is MIDCAB ready for a randomised trial?

      Statisticians argue that a randomised trial for a surgical procedure should not, and probably could not, be done during the evolutionary phase of the procedure when skills, experience, technique, philosophies, and even surgical biases of the surgeons are constantly changing. Any of these factors can have a significant effect on outcome,7 and the same randomised trial when repeated by different investigators can produce different results.

      This is likely to be the case should one compare MIDCAB with conventional revascularisation performed through median sternotomy. While the techniques of conventional surgery are largely uniform, those of MIDCAB vary significantly. Take for example the basic surgical approach used. Some surgeons use thoracoscopic mobilisation of the internal mammary artery while others use a range of techniques and instruments to perform the same task under direct vision, at the expense of not insignificant trauma to the chest wall.8Moreover, some excise a costal cartilage or two, but avoid the need for a rib spreader, while others use spreading that is only achieved by buckling some ribs. Is it correct to group all these techniques together in comparison to median sternotomy when we know for certain that spreading the ribs and not the size of skin incision is the main source of postoperative pain?9 Only recently an identical error occurred during the development of video-assisted thoracic surgical techniques,7 and the same trap should be avoided with MIDCAB. Indeed, the same issues apply to coronary angioplasty, which is also undergoing rapid evolution. Should we include coronary stenting in our trial, and if so which stent? One thing is certain, not all devices produce the same result.

      If given adequate time to mature before being subjected to a trial, it is conceivable that the procedure will become standardised. For instance, thoracoscopic mobilisation of the internal mammary artery will probably become the norm. How crucial is this? With thoracoscopy, full mobilisation of the internal mammary artery can be achieved easily, the length of the graft is not limited, and the need for mammary artery lengthening with other conduits, which has a very uncertain outcome, will die out. In addition, internal mammary artery avulsion10 or kinking at its attachment to the chest wall, when incompletely mobilised, are prevented.

      Currently, improved dedicated instruments are being developed and tested, and their use will not only reduce chest wall trauma to a truly minimally invasive level but will also facilitate performing the anastomoses, and ultimately improve the success of the procedure.11

      With MIDCAB still in its infancy, there is little doubt that a learning curve is involved, and current results are likely to represent the early phase of this process.12 13 Moreover, with more experience skills will develop, improving outcome beyond the learning zone.12

      Thus, it does not take a big leap of logic to deduce that, with time and further development, the results of MIDCAB will improve. Randomised controlled trials of MIDCAB against other treatments are obviously necessary, but the timing of such trials is crucial. Unless enough time is allowed for the best techniques to be developed and for surgeons to gain experience in their application, it will be difficult for MIDCAB to become a credible contender for the treatment of coronary artery disease. If we pass judgment too early, MIDCAB is bound to lose the vote of confidence.

      References

      View Abstract

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.